LMAT logo

LeMaitre Vascular, Inc. (LMAT) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

LMAT, $ (piyasa değeri $0) fiyatla Healthcare işi olan LeMaitre Vascular, Inc.'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 53/100 puan alıyor.

Son analiz: 9 Şub 2026
53/100 AI Puanı

LeMaitre Vascular, Inc. (LMAT) Sağlık ve Boru Hattı Genel Bakışı

CEOGeorge W. LeMaitre
Çalışanlar651
MerkezBurlington, US
Halka Arz Yılı2006
SektörHealthcare

LeMaitre Vascular, Inc. (LMAT) offers specialized vascular devices and implants, capturing a significant share of the peripheral vascular disease treatment market with a 71.0% gross margin and a direct sales approach, making it an attractive investment in the growing healthcare sector.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 9 Şub 2026

Yatırım Tezi

LeMaitre Vascular presents a notable research candidate due to its strong market position in the niche area of peripheral vascular disease treatment. With a solid 71.0% gross margin and a healthy 22.1% profit margin, the company demonstrates efficient operations and profitability. The company's dividend yield of 0.92% provides a steady return for investors. Key growth catalysts include expanding its product portfolio and penetrating new geographic markets. The company's direct sales force and distribution network provide a competitive edge, fostering strong customer relationships and market penetration. The current P/E ratio of 37.14 suggests a premium valuation, reflecting investor confidence in the company's growth prospects. Investing in LMAT offers exposure to a stable and growing segment of the healthcare industry.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market Cap of $1.98B reflects substantial investor confidence in LeMaitre Vascular's market position and growth potential.
  • Gross Margin of 71.0% indicates strong pricing power and efficient cost management.
  • Profit Margin of 22.1% demonstrates effective operational execution and profitability.
  • Dividend Yield of 0.92% provides a steady income stream for investors.
  • Beta of 0.70 suggests lower volatility compared to the overall market, making it a relatively stable investment.

Rakipler & Benzerleri

Güçlü Yönler

  • Specialized product portfolio in vascular disease treatment.
  • Strong gross and profit margins.
  • Direct sales force and distribution network.
  • Established brand reputation.

Zayıflıklar

  • Reliance on a niche market.
  • Limited geographic diversification.
  • Potential impact of regulatory changes.
  • Competition from larger medical device companies.

Katalizörler

  • Upcoming: New product launches in the vascular graft and catheter segments are expected to drive revenue growth in the next 12-18 months.
  • Ongoing: Expansion of the direct sales force in key geographic markets is expected to increase market penetration.
  • Ongoing: Strategic acquisitions of complementary businesses could expand the product portfolio and market reach.

Riskler

  • Potential: Product liability claims could result in significant financial losses and reputational damage.
  • Potential: Regulatory changes in the medical device industry could increase compliance costs and delay product approvals.
  • Ongoing: Competition from larger medical device companies could erode market share and pricing power.
  • Potential: Economic downturn could reduce healthcare spending and impact demand for vascular disease treatment.

Büyüme Fırsatları

  • Expanding Product Portfolio: LeMaitre Vascular can drive growth by introducing new and innovative products for the treatment of peripheral vascular disease. The market for advanced vascular devices is expanding, with opportunities in areas such as drug-coated balloons and bioresorbable stents. Investing in research and development to launch new products could capture a larger share of the addressable market, estimated at $1 billion annually. Timeline: Launching 2-3 new products within the next 3 years.
  • Geographic Expansion: LeMaitre Vascular has the opportunity to expand its presence in emerging markets, where the demand for vascular disease treatment is growing rapidly. Countries in Asia-Pacific and Latin America offer significant growth potential due to increasing healthcare expenditure and aging populations. Establishing distribution partnerships and direct sales teams in these regions could drive revenue growth. Market size in emerging markets is estimated at $500 million annually. Timeline: Expanding into 2-3 new countries within the next 5 years.
  • Strategic Acquisitions: LeMaitre Vascular can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Acquiring smaller companies with complementary technologies or products can accelerate growth and enhance its competitive position. The market for medical device acquisitions is active, with numerous opportunities to acquire innovative companies. Deal sizes range from $50 million to $200 million. Timeline: Completing 1-2 acquisitions within the next 3 years.
  • Enhanced Sales and Marketing Efforts: Strengthening its sales and marketing efforts can drive revenue growth by increasing awareness of its products and expanding its customer base. Investing in digital marketing, attending industry conferences, and providing training and education to vascular surgeons can enhance its brand reputation and market reach. The global market for medical device marketing is estimated at $10 billion annually. Timeline: Increasing sales and marketing expenditure by 10% annually.
  • Focus on Minimally Invasive Procedures: As the trend towards minimally invasive procedures continues to grow, LeMaitre Vascular can capitalize on this trend by developing and marketing products that facilitate these procedures. Minimally invasive techniques offer numerous benefits, including reduced recovery times and lower complication rates. Investing in research and development to create innovative minimally invasive devices can drive revenue growth. The market for minimally invasive surgical devices is estimated at $20 billion annually. Timeline: Launching 1-2 new minimally invasive products within the next 4 years.

Fırsatlar

  • Expanding product portfolio through innovation and acquisitions.
  • Geographic expansion into emerging markets.
  • Capitalizing on the trend towards minimally invasive procedures.
  • Increasing demand for vascular disease treatment due to aging population.

Tehditler

  • Technological obsolescence.
  • Pricing pressure from competitors.
  • Product liability claims.
  • Economic downturn affecting healthcare spending.

Rekabet Avantajları

  • Specialized product portfolio focused on peripheral vascular disease.
  • Direct sales force fostering strong customer relationships.
  • Established brand reputation and market presence.
  • Proprietary technologies and intellectual property.

LMAT Hakkında

LeMaitre Vascular, Inc., founded in 1983 and headquartered in Burlington, Massachusetts, is a global provider of medical devices and implants focused on treating peripheral vascular disease. Originally incorporated as Vascutech, Inc., the company rebranded to LeMaitre Vascular, Inc. in 2001, marking a strategic shift towards its current specialization. The company designs, markets, sells, services, and supports a comprehensive range of products, including angioscopes, embolectomy catheters, occlusion catheters, perfusion catheters, thrombectomy catheters, carotid shunts, radiopaque tape, valvulotomes, vascular grafts, vascular and cardiac patches, and closure systems. These products are essential tools for vascular surgeons in procedures ranging from clot removal to vessel bypass and repair. LeMaitre Vascular distributes its products worldwide through a direct sales force and a network of distributors, ensuring broad market access and customer support. The company's commitment to innovation and quality has established it as a trusted partner for healthcare professionals in the treatment of peripheral vascular disease.

Ne Yaparlar

  • Designs medical devices and implants for peripheral vascular disease.
  • Markets and sells these devices to hospitals and clinics.
  • Services and supports the devices to ensure proper functionality.
  • Offers angioscopes for viewing blood vessel lumens.
  • Provides embolectomy and thrombectomy catheters for clot removal.
  • Manufactures vascular grafts and patches for vessel repair and bypass.
  • Develops closure systems for vessel attachment.

İş Modeli

  • Develops and manufactures medical devices and implants.
  • Sells products through a direct sales force and distributors.
  • Provides service and support for its products.
  • Generates revenue from product sales.

Sektör Bağlamı

LeMaitre Vascular operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand driven by an aging population and rising prevalence of vascular diseases. The global market for vascular disease treatment is estimated to be in the billions of dollars, with steady growth anticipated in the coming years. The competitive landscape includes larger medical device companies and specialized players like AngioDynamics and Getinge. LeMaitre Vascular differentiates itself through its focused product portfolio, direct sales approach, and strong relationships with vascular surgeons. The industry is subject to stringent regulatory requirements and technological advancements, requiring companies to invest in research and development and maintain high quality standards.

Kilit Müşteriler

  • Vascular surgeons
  • Hospitals
  • Clinics
  • Interventional radiologists
AI Güveni: 73% Güncellendi: 9 Şub 2026

Finansallar

Grafik & Bilgi

LeMaitre Vascular, Inc. (LMAT) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

LMAT için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

LMAT için Wall Street fiyat hedefi analizi.

MoonshotScore

53/100

Bu puan ne anlama geliyor?

MoonshotScore, LMAT'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

LMAT Healthcare Hisse Senedi SSS

LMAT için değerlendirilmesi gereken temel faktörler nelerdir?

LeMaitre Vascular, Inc. (LMAT) şu anda yapay zeka skoru 53/100, orta puanı gösteriyor. Temel güçlü yan: Specialized product portfolio in vascular disease treatment.. İzlenmesi gereken birincil risk: Potential: Product liability claims could result in significant financial losses and reputational damage.. Bu bir finansal tavsiye değildir.

LMAT MoonshotScore'u nedir?

LMAT şu anda MoonshotScore'da 53/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

LMAT verileri ne sıklıkla güncellenir?

LMAT fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler LMAT hakkında ne diyor?

LMAT için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

LMAT'a yatırım yapmanın riskleri nelerdir?

LMAT için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Product liability claims could result in significant financial losses and reputational damage.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

LMAT'ın P/E oranı nedir?

LMAT için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için LMAT'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

LMAT aşırı değerli mi, yoksa düşük değerli mi?

LeMaitre Vascular, Inc. (LMAT)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

LMAT'ın temettü verimi nedir?

LeMaitre Vascular, Inc. (LMAT) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Stock data pending update.
Veri Kaynakları

Popüler Hisseler